Laser Treatment for Vision Loss from Branch Retinal Vein Occlusion
is Safer than Corticosteroid Injections
Study shows that Laser Treatment is both safer and equally effective
FOR IMMEDIATE RELEASE
Caroline Baumal, MD
"As a result of the SCORE study results for blockage of a branch of the retinal vein, there are more viable treatment options now available including laser or intravitreal steroid injection. The treatment choice may vary depending on the clinical circumstances in the individual," said Caroline Baumal, M.D., Assistant Professor at the Tufts University School of Medicine and a Principal Investigator of the SCORE study.
Eye doctors typically treat BRVO with laser therapy applied to the affected retina in a grid pattern. However, some ophthalmologists have treated people who have BRVO using eye injections of an anti-inflammatory corticosteroid called triamcinolone. Because clinical observations suggested a visual benefit, the SCORE study was initiated to compare the safety and effectiveness of standard care laser treatment with two different doses of triamcinolone—1 milligram and 4 milligrams. The results appear in the September 2009 issue of Archives of Ophthalmology, published alongside findings from a separate trial within the SCORE study, which looked at blockages in larger retinal veins.
Participants in the study included 411 people with BRVO who were an average of 67 years old. Patients could receive treatment every four months for up to three years. One year after patients began the trial, equal numbers of patients experienced visual improvement in each treatment group. Twenty to 30 percent of patients in each group experienced substantial visual gains of three or more lines on a vision chart—equivalent to identifying letters that were half as small as they could read before treatment.
However, patients who received either dosage of corticosteroid medication were more likely to develop a cataract or have an increase in eye pressure requiring medication than patients who received laser treatment. Between one and two years after treatment was begun, patients who received the 4 milligram dosage were also more likely to undergo cataract surgery.
"These results may have a significant public health impact by providing guidance for clinicians and patients in their selection of a branch retinal vein occlusion treatment," said Frederick L. Ferris III, M.D., clinical director of the NEI. "Still, better treatments for this condition are needed. This information could guide future clinical trials of new and more effective treatments for BRVO patients."
The SCORE study was co-chaired by Michael S. Ip, M.D., associate professor at the
# # #
The New England Eye Center (NEEC), is the ophthalmology department at
National Eye Institute
The National Eye Institute (NEI), part of the National Institutes of Health, leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit www.nei.nih.gov.
The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
# # #
Contact: William R. Sacco,
(617) 636-1055 or email@example.com
Contact: National Eye Institute
(301) 496-5248 or firstname.lastname@example.org